Upregulation of α-synuclein during localized radiation therapy signals the association of cancer-related fatigue with the activation of inflammatory and neuroprotective pathways

Brain, Behavior, and Immunity

Volumn 27, Issue 1, 2013, Pages 63-70

  Saligan, L N ^a   Hsiao, C P ^a   Wang, D ^a   Wang, X M ^a   John, L St ^a   Kaushal, A ^b   Citrin, D ^b   Barb, J J ^c   Munson, P J ^c   Dionne, R A ^a  

^a NATIONAL INSTITUTE OF NURSING RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cancer related fatigue; Fatigue; Gene expression; Genomic; Neuroinflammation

Indexed keywords

ALPHA SYNUCLEIN;

ARTICLE; CANCER FATIGUE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTERNAL BEAM RADIOTHERAPY; GENE EXPRESSION PROFILING; GENETIC CORRELATION; HUMAN; MALE; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATIGUE; GENE EXPRESSION PROFILING; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; UP-REGULATION;

EID: 84870766137     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2012.09.009     Document Type: Article

References (41)

1. Bokemeyer M., Ding X.Q., Goldbecker A., Raab P., Heeren M., Arvanitis D., et al. Evidence for neuroinflammation and neuroprotection in HCV infection-associated encephalopathy. Gut 2011, 60:370-377.
2. Bower J., Ganz P., Aziz N., Olmstead R., Irwin M.R., Cole S.W. Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids. Brain Behav. Immun. 2007, 21:251-258.
3. Bruera E., Driver L., Barnes E.A., Willey J., Shen L., Palmer J.L., et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J. Clin. Oncol. 2003, 21:4439-4443.
4. Bruera E., Valero V., Driver L., Shen L., Willey J., Zhang T., et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J. Clin. Oncol. 2006, 24:2073-2078.
5. Burre J., Sharma M., Tsetsenis T., Buchman V., Etherton M.R., Sudhoff T.C. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 2010, 329:1663-1667.
6. Butler J.M., Case L.D., Atkins J., Frizzell B., Sanders G., Griffin P. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2007, 69:1496-1501.
7. Campbell T., Blasko J., Crawford E.D., Forman J., Hanks G., Kuban D., et al. Clinical staging of prostate cancer: reproducibility and clarification of issues. Int. J. Cancer 2001, 96:198-209.
8. Danjoux C., Gardner S., Fitch M. Prospective evaluation of fatigue during a course of curative radiotherapy for localised prostate cancer. Support. Care Cancer 2007, 15:1169-1176.
9. Fagundes C.P., Murray D.M., Hwang B.S., Gouin J.P., Thayer J.F., Sollers J.J., et al. Sympathetic and parasympathetic activity in cancer-related fatigue: more evidence for a physiological substrate in cancer survivors. Psychoneuroendocrinology 2011, 36:1137-1147.
10. Gao H.M., Zhang F., Zhou H., Kam W., Wilson B., Hong J.S. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ. Health Perspect. 2011, 119:807-814.
11. Goldstein D. Stress, allostatic load, catecholamines, and other neurotransmitters in neurodegenerative diseases. Endocrinol. Regul. 2011, 45:91-98.
12. Greenberg D.B., Sawicka J., Eisenthal S., Ross D. Fatigue syndrome due to localized radiation. J. Pain Symptom Manage. 1992, 7:38-45.
13. Grover V.P., Pavese N., Koh S.B., Wylezinska M., Saxby B.K., Gerhard A., et al. Cerebral microglial activation in patients with hepatitis c: in vivo evidence of neuroinflammation. J. Viral Hepat. 2012, 19:e89-96.
14. Hanna A., Sledge G., Mayer M.L., Hanna N., Einhorn L., Monahan P., et al. A phase II study of methylphenidate for the treatment of fatigue. Support. Care Cancer 2006, 14:210-215.
15. Hashimoto M., Hsu L.J., Xia Y., Takeda A., Sisk A., Sundsmo M., et al. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro. NeuroReport 1999, 10:717-721.
16. Hashimoto M., Hsu L.J., Rockenstein E., Takenouchi T., Mallory M., Masliah E. Alpha-synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells. J. Biol. Chem. 2002, 277:11465-11472.
17. Hsu L.J., Sagara Y., Arroyo A., Rockenstein E., Sisk A., Mallory M., et al. Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 2000, 157:401-410.
18. Leng Y., Chase T.N., Bennett M.C. Muscarinic receptor stimulation induces translocation of an alpha-synuclein oligomer from plasma membrane to a light vesicle fraction in cytoplasm. J. Biol. Chem. 2001, 276:28212-28218.
19. Li W., Lesuisse C., Xu Y., Troncoso J.C., Price D.L., Lee M.K. Stabilization of alpha-synuclein protein with aging and familial Parkinson's disease-linked A53T mutation. J. Neurosci. 2004, 24:7400-7409.
20. Linnertz C., Saucier L., Ge D., Cronin K.D., Burke J.R., Browndyke J.N., et al. Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues. PLoS One 2009, 4:e7480.
21. Lydiatt W.M., Denman D., McNeilly D.P., Puumula S.E., Burke W.J. A randomized, placebo-controlled trial of citalopram for the prevention of major depression during treatment for head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 2008, 134:528-535.
22. Manning-Bog A.B., McCormack A.L., Purisai M.G., Bolin L.M., Di Monte D.A. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J. Neurosci. 2003, 23:3095-3099.
23. Mar Fan H.G., Clemons M., Xu W., Chemerynsky I., Breunis H., Braganza S., et al. A randomized, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support. Care Cancer 2008, 16:577-583.
24. Miaskowski C., Paul S.M., Cooper B.A., Lee K., Dodd M., West C., et al. Trajectories of fatigue in men with prostate cancer before, during, and after radiation therapy. J. Pain Symptom Manage. 2008, 35:632-643.
25. Mitchell S.A. Cancer-related fatigue: state of the science. PM&R 2010, 2:364-383.
26. Mock V., Atkinson A., Barsevick A., Cella D., Cimprich B., Cleeland C., et al. NCCN practice guidelines for cancer-related fatigue. Oncology 2000, 14:151-161.
27. Monga U., Kerrigan A.J., Thornby J., Monga T.N. Prospective study of fatigue in localized prostate cancer patients undergoing radiotherapy. Radiat. Oncol. Invest. 1999, 7:178-185.
28. Monti B., Polazzi E., Batti L., Crochemore C., Virgili M., Contestabile A. Alpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine-induced death. J. Neurochem. 2007, 103:518-530.
29. Musgrove R.E., King A.E., Dickson T.C. Neuroprotective upregulation of endogenous alpha-synuclein precedes ubiquitination in cultured dopaminergic neurons. Neurotox. Res. 2011, 19:592-602.
30. Nemani V.M., Lu W., Berge V., Nakamura K., Onoa B., Lee M.K., et al. Increasing expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic reclustering after endocytosis. Neuron 2010, 65:66-79.
31. Olivares D., Huang X., Branden L., Greig N.H., Rogers J.T. Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron-mediated oxidative stress; the role of a putative iron-responsive element. Int. J. Mol. Sci. 2009, 10:1226-1260.
32. Piper B.F., Dibble S.L., Dodd M.J., Weiss M.C., Slaughter R.E., Paul S.M. The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol. Nurs. Forum 1998, 25(677-684):1998.
33. Quinn J.G., Coulson D.T., Brockbank S., Beyer N., Ravid R., Hellemans J., et al. α-Synuclein mRNA and soluble α-synuclein protein levels in post-mortem brain from patients with Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease. Brain Res. 2012, 1459:71-80.
34. Rönnbäck L., Hansson E. On the potential role of glutamate transport in mental fatigue. J. Neuroinflammation 2004, 1:22.
35. Smets E.M., Visser M.R., Willems-Groot A.F., Garssen B., Oldenburger F., van Tienhoven G. Fatigue and radiotherapy: experience in patients undergoing treatment. Br. J. Cancer 1998, 78:899-906.
36. Sulzer D. Clues to how alpha-synuclein damages neurons in Parkinson's disease. Mov. Disord. 2010, 25(Suppl 1):S27-S31.
37. Thompson I., Thrasher J.B., Aus G., Burnett A.L., Canby-Haqino E.D., Cookson M.S., et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J. Urol. 2007, 177:2106-2131.
38. Wang X.M., Wu T.X., Hamza M., Ramsay E.S., Wahl S.M., Dionne R.A. Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain 2007, 128:136-147.
39. Westerlund M., Belin A.C., Anvret A., Hakansson A., Nissbrandt H., Lind C., et al. Cerebellar alpha-synuclein levels are decreased in Parkinson's disease and do not correlate with SNCA polymorphisms associated with disease in a Swedish material. FASEB J. 2008, 22:3509-3514.
40. Wilker E., Yaffe M.B. 14-3-3 proteins - a focus on cancer and human disease. J. Mol. Cell. Cardiol. 2004, 37(633-642):2004.
41. Wratten C., Kilmurray J., Nash S., Seldon M., Hamilton C.S., O'Brien P.C., et al. Fatigue during breast radiotherapy and its relationship to biological factors. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59:160-167.